Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov 4:15:143.
doi: 10.1186/s12872-015-0137-7.

Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach

Carmen Suárez Fernández, Francesc Formiga  1 , Miguel Camafort  2 , María Cepeda Rodrigo, Jesús Díez-Manglano  3 , Antonio Pose Reino, Gregorio Tiberio  4 , Jose María Mostaza  5 ; Grupo de trabajo de Riesgo vascular de la SEMI
Affiliations

Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach

Carmen Suárez Fernández et al. BMC Cardiovasc Disord. .

Erratum in

Abstract

Background: Atrial fibrillation (AF) in the elderly is a complex condition. It has a direct impact on the underuse of antithrombotic therapy reported in this population.

Discussion: All patients aged ≥75 years with AF have an individual yearly risk of stroke >4 %. However, the risk of hemorrhage is also increased. Moreover, in this population it is common the presence of other comorbidities, cognitive disorders, risk of falls and polymedication. This may lead to an underuse of anticoagulant therapy. Direct oral anticoagulants (DOACs) are at least as effective as conventional therapy, but with lesser risk of intracranial hemorrhage. The simplification of treatment with these drugs may be an advantage in patients with cognitive impairment. The great majority of elderly patients with AF should receive anticoagulant therapy, unless an unequivocal contraindication. DOACs may be the drugs of choice in many elderly patients with AF. In this manuscript, the available evidence about the management of anticoagulation in elderly patients with AF is reviewed. In addition, specific practical recommendations about different controversial issues (i.e. patients with anemia, thrombocytopenia, risk of gastrointestinal bleeding, renal dysfunction, cognitive impairment, risk of falls, polymedication, frailty, etc.) are provided.

PubMed Disclaimer

References

    1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–2375. doi: 10.1001/jama.285.18.2370. - DOI - PubMed
    1. Barrios V, Calderón A, Escobar C, de la Figuera M. Patients with atrial fibrillation in a primary care setting: Val-FAAP study. Rev Esp Cardiol. 2012;65(1):47–53. doi: 10.1016/j.recesp.2011.08.008. - DOI - PubMed
    1. Shao XH, Yang YM, Zhu J, Zhang H, Liu Y, Gao X, et al. Comparison of the clinical features and outcomes in two age-groups of elderly patients with atrial fibrillation. Clin Interv Aging. 2014;9:1335–1342. doi: 10.2147/CIA.S67123. - DOI - PMC - PubMed
    1. Wändell PE, Carlsson AC, Sundquist J, Johansson SE, Bottai M, Sundquist K. Pharmacotherapy and mortality in atrial fibrillation-a cohort of men and women 75 years or older in Sweden. Age Ageing. 2015;44(2):232–238. doi: 10.1093/ageing/afu153. - DOI - PubMed
    1. Reiffel JA. Atrial fibrillation and stroke: epidemiology. Am J Med. 2014;127(4):e15–e16. - PubMed

Publication types

MeSH terms